Rani Therapeutics Reports the Results for RT-111 Capsules Containing CT-P43 (biosimilar, ustekinumab) in P-I Trial for the Treatment of Various Indications

Shots:  

• The P-I clinical trial evaluates the safety & efficacy of RT-111 in delivering CT-P43 (biosimilar, ustekinumab) in patients with moderate to severe plaque psoriasis, active psoriatic arthritis & IBD 

• As per the results, RT-111 delivered CT-P43 in a dose proportional manner with high bioavailability & depicted a higher Cmax & shorter Tmax vs ustekinumab delivered by SC injection 

• RT-11 is a RaniPill capsule that contains CT-P43, a biosimilar of Ustekinumab, a human IgG1қ mAb that functions by binding with specificity to the p40 protein subunit used by both the IL-12 & IL-23 cytokines 

Ref: Rani Therapeutics| Image: Rani Therapeutics | Press Release

Related News:- Samsung Bioepis Signs a Collaboration Agreement with Samil Pharma to Co-Commercialize SB15 (biosimilar, aflibercept) for the Treatment of Ophthalmologic Conditions

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com